CNS Response completes enrollment in depression study

US-based healthcare company CNS Response has completed enrollment at 14 study sites for its treatment-resistant depression clinical trial. This reportedly puts the company on track to complete the trial in September 2009 and release top-line results before year-end of 2009.

Daniel Hoffman, president and chief medical officer of CNS Response, said: "Completion of our clinical trial is an important milestone for CNS Response. Physicians using Referenced-EEG are achieving better patient outcomes and, according to the United BioSource study, Referenced-EEG already offers superior evidence for treatment-resistant depression.

"Our current clinical trial will bring this technology to the attention of the nation's top academic and clinical psychiatrists."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: academic, clinical, depression, healthcare, physicians, president, technology, track, trial